Applying Recent Therapeutic Advancements into Personalized Treatment Plans in IPF

This CME program will cover information presented at the 2015 ATS Annual Meeting. The faculty discuss data presented at the meeting and how physicians can apply this data in their practice. Information regarding the mechanism of IPF and possible biological markers for the disease is presented. Current clinical trial data and available treatment options are analyzed. The risk factors associated with certain therapies as well as adverse events are reviewed and presented in a way that allows physicians to integrate the data into everyday practice. This program will give physicians the opportunity to develop personalized treatment plans for their IPF patients based on the most recent data.


Pulmonologists, respiratory specialists, primary care physicians, and other healthcare clinicians responsible for the care of patients with IPF.


Upon completion of this activity, participants will be able to:

  1. Review the histologic and progressive process of IPF, and examine treatment guidelines, diagnostic characteristics, and patient screening recommendations.
  2. Analyze current clinical trial data within IPF, and identify the role of pharmacotherapies in treatment.
  3. Develop personalized treatment plans to optimally address risk, adverse events, and overall quality of life for patients with IPF.


Gerard J. Criner, MD
Professor and Chair
Department of Thoracic Medicine and Surgery

Temple University School of Medicine
Philadelphia, PA

Fernando J. Martinez, MD
Gladys and Roland Harriman Professor of Medicine
Executive Vice Chair
Department of Medicine
Weill Cornell Medical Center
New York City, NY


Victor J. Thannickal, MD
Professor of Medicine and Pathology
Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease
Director, Division of Pulmonary, Allergy, and Critical Care
University of Alabama at Birmingham
Birmingham, AL



Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Relationship Identified With:

Gerard J. Criner, MD

Nothing to disclose

Fernando J. Martinez, MD


Consultant/Advisor: Amgen Inc.; AstraZeneca; Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc; Forest Laboratories, Inc; Genentech, Inc; GlaxoSmithKline plc; Ikaria, Inc.

Grant/Research Support: AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc; Forest Laboratories, Inc; GlaxoSmithKline plc; Stromedix; Takeda Pharmaceutical Company Limited

Royalties/Patents: UpToDate, Inc.

Speakers Bureau: Annenberg Media; California Society of Allergy, Asthma, and Immunology; Falco; Haymarket Media Group; Miller; National Association for Continuing Education; University of Michigan; Western Society of Allergy, Asthma, and Immunology


Victor J. Thannickal, MD


Consultant/Advisor: Boehringer Ingelheim Pharmaceuticals, Inc/DMC

Grant/Research Support: Biogen Idec; National Institute of Health Grants

Planners, Managers, ReviewersSandy Breslow; Brynne Hunter; Alison Kemp; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Jaimie Kelly; and Bernard M. Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

Financial Support

This activity has been supported by an independent educational grant from Genentech, Inc.

Provider Information 

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

Course Open Date: August 10, 2015 | Course Expiration Date: August 9, 2016

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 


For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Genentech, Inc. do not recommend the use of any agent outside of the labeled indications. 

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Please login or register to take this course.